2,149 institutions hold shares in Gilead Sciences Inc. (GILD), with 1.38M shares held by insiders accounting for 0.11% while institutional investors hold 80.16% of the company’s shares. The shares outstanding are 1.26B, and float is at 1.25B with Short Float at 1.72%. Institutions hold 80.07% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Capital Research Global Investors with over 117.11 million shares valued at $7.4 billion. The investor’s holdings represent 9.34% of the GILD Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 111.18 million shares valued at $6.48 billion to account for 8.87% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 102.72 million shares representing 8.19% and valued at over $6.49 billion, while State Street Corporation holds 4.55% of the shares totaling 56.99 million with a market value of $3.6 billion.
Gilead Sciences Inc. (NASDAQ: GILD) is 10.49% higher on its value in year-to-date trading and has touched a low of $56.56 and a high of $85.97 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The GILD stock was last observed hovering at around $65.23 in the last trading session, with the day’s loss setting it -0.86% off its average median price target of $73.00 for the next 12 months. It is also 35.63% off the consensus price target high of $100.00 offered by 32 analysts, but current levels are -9.1% lower than the price target low of $59.00 for the same period.
Currently trading at $64.37, the stock is -2.84% and 2.54% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.05 million and changing -1.32% at the moment leaves the stock -3.97% off its SMA200. GILD registered -3.93% loss for a year compared to 6-month gain of -2.02%. The firm has a 50-day simple moving average (SMA 50) of $64.97 and a 200-day simple moving average (SMA200) of $63.03.
The stock witnessed a -5.32% loss in the last 1 month and extending the period to 3 months gives it a 5.58%, and is -3.81% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.97% over the week and 2.32% over the month.
Gilead Sciences Inc. (GILD) has around 11800 employees, a market worth around $81.77B and $24.69B in sales. Current P/E ratio is 825.26 and Fwd P/E is 9.50. Profit margin for the company is -1.00%. Distance from 52-week low is 13.81% and -25.13% from its 52-week high. The company has generated returns on investments over the last 12 months (9.50%).
Gilead Sciences Inc. (GILD) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Gilead Sciences Inc. (GILD) is a “Overweight”. 32 analysts offering their recommendations for the stock have an average rating of 2.40, where 16 rate it as a Hold and 1 think it is a “Overweight”. 13 of the analysts rate the stock as a “Buy”. 2 analysts have rated the stock as a Sell or Underperform.
Gilead Sciences Inc. is expected to release its quarterly report on 05/04/2021 and quarterly earnings per share for the current quarter are estimated at $2.02 with sales reaching $6.68B over the same period.The EPS is expected to grow by 1.10% this year, but quarterly earnings will post 0.40% year-over-year. Quarterly sales are estimated to grow 20.50% in year-over-year returns.
Gilead Sciences Inc. (GILD) Insider Activity
A total of 34 insider transactions have happened at Gilead Sciences Inc. (GILD) in the last six months, with sales accounting for 13 and purchases happening 21 times. The most recent transaction is an insider sale by Pletcher Brett A, the company’s EVP,Corp Affairs & Gen Counsel. SEC filings show that Pletcher Brett A sold 1,975 shares of the company’s common stock on Feb 10 at a price of $67.41 per share for a total of $0.13 million. Following the sale, the insider now owns 28832.0 shares.
Gilead Sciences Inc. disclosed in a document filed with the SEC on Feb 01 that Pletcher Brett A (EVP,Corp Affairs & Gen Counsel) sold a total of 9,711 shares of the company’s common stock. The trade occurred on Feb 01 and was made at $65.97 per share for $0.64 million. Following the transaction, the insider now directly holds 28832.0 shares of the GILD stock.
Still, SEC filings show that on Aug 17, Parsey Merdad (Chief Medical Officer) disposed off 182 shares at an average price of $68.32 for $12434.0. The insider now directly holds 0 shares of Gilead Sciences Inc. (GILD).
Gilead Sciences Inc. (GILD): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 41.49% up over the past 12 months. Johnson & Johnson (JNJ) is 9.85% up on the 1-year trading charts. Short interest in the company’s stock has risen 0.05% from the last report on Dec 30, 2020 to stand at a total of 21.57 million short shares sold with a short interest ratio of 2.16.